{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-24-000065","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2024-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.371632+00:00","generated_at":"2026-06-04T02:43:23.455882+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MacroGenics Phase 2 TAMARACK safety data shows improved tolerability at lower vobra duo doses","bullets":["Drug interruption rate 12.6% vs 58.5% at 12 weeks in Phase 1; discontinuation 5.3% vs 14.6%.","No fatal AEs; most common TEAEs: asthenia (40.7%), nausea (27.7%), fatigue (20.3%).","ASCO abstract not accepted; plan to share updated interim safety + efficacy by May 31, 2024.","rPFS primary endpoint data expected Fall 2024; IDMC recommended study continue unchanged.","Enrolled 182 mCRPC patients across 2.0 and 2.7 mg/kg Q4W dose arms; 85.7% still on treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-24-000065","json":"https://secwatch.observer/filing/0001125345-24-000065.json","markdown":"https://secwatch.observer/filing/0001125345-24-000065.md","text":"https://secwatch.observer/filing/0001125345-24-000065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534524000065/0001125345-24-000065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534524000065/mgnx-20240403.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:43:23.455882+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}